Patent · US Active

Human FcRn-binding modified antibodies and methods of use

US11091541B2 · kind B2 · utility

2Cited by

8References

7Claims

0Family size

Assignee

Hoffmann-La Roche Inc. · US

Inventors

Guido Hartmann · Soest, DE
Joerg Thomas Regula · Munich, DE
Matthias Rueth · Penzberg, DE
Wolfgang Schaefer · Sankt Augustin, DE
Tilman Schlothauer

Key dates

Filing date	Oct 29, 2015
Grant date	Aug 17, 2021
Priority date	—
Expiry date	Dec 18, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Herein is reported the use of an antibody comprising an Fc-region with abolished FcRn binding for the transport of a soluble receptor ligand from the eye over the blood-ocular-barrier into the blood circulation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.